Literature DB >> 14871222

Cutaneous leukemia inhibitory factor and its potential role in the development of skin tumors.

Roddie C McKenzie1, Jacek Szepietowski.   

Abstract

Leukemia inhibitory factor (LIF) is a polyfunctional cytokine with a variety and a diverse range of biological activities. However, this is a reflection of the fact that the cytokine is expressed in many different tissues, has a wide target cell range, and fulfills different functions in different tissues. The purpose of this article is to examine what is known about LIF expression in the skin and to consider whether LIF plays a role in inflammatory and hyperplastic events in the skin. LIF is strongly expressed in skin tumors, and recent studies indicate that it may affect tumor growth by several different mechanisms. The biological activities of LIF relevant to carcinogenesis, its expression, and signal transduction by the LIF receptor are described. Expression of LIF in normal skin by skin tumors and its induction by ultraviolet radiation and proinflammatory stimuli are discussed, as are possible interactions between LIF, mast cells, and tumor growth. We consider what role LIF and other members of the hemopoietin family of cytokines play in healthy and diseased skin and whether LIF could play a role in hyperplastic skin disorders. LIF appears to be an important cytokine for normal keratinocyte growth and wound healing and may be involved in regulating the proliferation of skin tumors. Accordingly, LIF may be a useful target for anticancer therapy and as a growth factor for normal skin during reconstructive surgery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871222     DOI: 10.1111/j.1524-4725.2004.30087.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  9 in total

1.  Expression of interleukin-11 and interleukin-11 receptor alpha in human colorectal adenocarcinoma; immunohistochemical analyses and correlation with clinicopathological factors.

Authors:  Kazuyuki Yamazumi; Toshiyuki Nakayama; Takafumi Kusaba; Chun Yang Wen; Ayumi Yoshizaki; Yuichi Yakata; Takeshi Nagayasu; Ichiro Sekine
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

2.  Tenascin-X and leukemia inhibitory factor receptor are down-regulated in leiomyoma compared with normal myometrium.

Authors:  Sun Ok Lee; Soo Yoon Lee; Sa Ra Lee; Woong Ju; Seung Cheol Kim
Journal:  J Gynecol Oncol       Date:  2008-06-20       Impact factor: 4.401

Review 3.  LIF-dependent signaling: new pieces in the Lego.

Authors:  Marie-Emmanuelle Mathieu; Claire Saucourt; Virginie Mournetas; Xavier Gauthereau; Nadine Thézé; Vincent Praloran; Pierre Thiébaud; Hélène Bœuf
Journal:  Stem Cell Rev Rep       Date:  2012-03       Impact factor: 5.739

4.  The leukemia inhibitory factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in human cutaneous melanoma.

Authors:  Laure Humbert; Mostafa Ghozlan; Lucie Canaff; Jun Tian; Jean-Jacques Lebrun
Journal:  BMC Cancer       Date:  2015-03-29       Impact factor: 4.430

5.  HIF-2α mediates hypoxia-induced LIF expression in human colorectal cancer cells.

Authors:  Lihua Wu; Haiyang Yu; Yuhan Zhao; Cen Zhang; Jiabei Wang; Xuetian Yue; Qifeng Yang; Wenwei Hu
Journal:  Oncotarget       Date:  2015-02-28

6.  Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation.

Authors:  Stuart Duncan Morton; Massimiliano Cadamuro; Simone Brivio; Marta Vismara; Tommaso Stecca; Marco Massani; Nicolò Bassi; Alberto Furlanetto; Ruth Elizabeth Joplin; Annarosa Floreani; Luca Fabris; Mario Strazzabosco
Journal:  Oncotarget       Date:  2015-09-22

7.  Leukemia inhibitory factor regulates marmoset induced pluripotent stem cell proliferation via a PI3K/‌Akt‑dependent Tbx‑3 activation pathway.

Authors:  Minxia Ke; Quan He; Danping Hong; Ouyang Li; Mengyi Zhu; Wen-Bin Ou; Yulong He; Yuehong Wu
Journal:  Int J Mol Med       Date:  2018-04-03       Impact factor: 4.101

Review 8.  Leukemia Inhibitory Factor: An Important Cytokine in Pathologies and Cancer.

Authors:  Megan M Jorgensen; Pilar de la Puente
Journal:  Biomolecules       Date:  2022-01-27

9.  LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway.

Authors:  Xiaoyan Li; Qifeng Yang; Haiyang Yu; Lihua Wu; Yuhan Zhao; Cen Zhang; Xuetian Yue; Zhen Liu; Hao Wu; Bruce G Haffty; Zhaohui Feng; Wenwei Hu
Journal:  Oncotarget       Date:  2014-02-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.